Company has a drug that now works for three indications and is human trials with first safety read outs in 3 weeks in a 60 billion dollar unmet market with intellectual protection now as their patent application moves down the line
The above tells you already company is on a winner. To be trading at a penny valuation at prices where you have biotechs trading for 2-3 billion dollar markets still in preclinical stages and with huge competition for their medication. NYR currently has no approved competition in a 60 billion dollar market and clearing human safety. Valuation is rubbish even in this rubbish market
NYR Price at posting:
9.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)